Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

ConditionsPrimary Open Angle Glaucoma (POAG)Ocular Hypertension

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age19+

SponsorHuons Co., Ltd.

About this trial

A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 19 years and older

Participants diagnosed with POAG or OH

Have fully explained and understood the study and have voluntarily given written informed consent.

Disqualifiers

Acute or chronic angle-closure glaucoma

Congenital glaucoma, secondary glaucoma (open-angle glaucoma)

Trial design

Design model

Parallel

Treatments tested in this trial

HUC3-637
Drug
Ophthalmic solution instilled directly into the eye (topical ocular administration)
HUC3-637-R
Drug
Ophthalmic solution instilled directly into the eye (topical ocular administration)

Treatment groups

206 Participants

are divided into 2 treatment groups

Group A: HUC3-637Experimental treatment 1 intervention

Group B: HUC3-637-RActive comparator 1 intervention

Trial outcomes

Primary outcomes

Mean change in diurnal IOP

Time frame

12 week

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Huons Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov

Apply now